Business
Resverlogix Honoured with World Economic Forum Technology Pioneer Award
ApoA-I technology is recognized for its ability to transform the treatment of cardiovascular dise...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\nApoA-I technology is recognized for its ability to transform the\n\n\ntreatment of cardiovascular disease\n\n\nTSX Exchange Symbol: RVX\n\n\nCALGARY, Nov. 29 /CNW/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is\npleased to announce today that the World Economic Forum has selected\nResverlogix as a winner of the very prestigious Technology Pioneer Award in\nrecognition of its NexVas(TM) Plaque Removal program. Candidates for this\naward must be involved in the development of life-changing technologies and\nhave potential for long-term impact on business and society.\n\n\n"We are elated to receive this high-level recognition from such an\nimportant leading global body as the World Economic Forum. This awareness that\nour innovative technology could have such a dramatic positive impact for\nsociety, as it relates to the future treatment of cardiovascular disease\n(CVD), further validates the positive direction of our NexVas technology,"\nstated Mr. Donald McCaffrey, President, CEO & Co-Founder of Resverlogix.\n\n\nResverlogix was selected because it is developing exceptionally promising\nnew molecules that increase the production of ApoA-l and high density\nlipoprotein (HDL) for the treatment of atherosclerosis. According to the World\nHealth Organization, CVD is the number one cause of death globally, an immense\nproblem currently responsible for killing nearly 18 million people annually\nworldwide.\n\n\n"I would like to offer Canada's sincere congratulations to Resverlogix\nfor winning this international award from the World Economic Forum," said the\nHonourable Minister Jim Prentice, Minister of Industry. "Resverlogix is doing\nsome incredible work in advancing the treatment of atherosclerosis, the major\nunderlying cause of cardiovascular disease and this award is a testament to\nCanada's world-class biopharmaceutical industry."\n\n\nDr. Norman Wong, M.D., Co-Founder of Resverlogix added, "Current\ntherapies have made significant strides in improving outcomes but are only\nable to address 30 percent of the risk associated with CVD. Consequently there\nexists a significant unmet medical need for a therapy to address the remaining\n70 percent of risk. The proven ability of our drug to increase the production\nof ApoA-I and functional HDL, offers enormous potential to addr...